Log In
Print
BCIQ
Print
Print this Print this
 

ImMucin (VXL100)

  Manage Alerts
Collapse Summary General Information
Company Vaxil BioTherapeutics Ltd.
Description21mer synthetic vaccine composed of the entire signal peptide domain of the mucin 1 (MUC1; CD227) protein
Molecular Target Mucin 1 (MUC1) (CD227)
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase I/II
Standard IndicationMultiple myeloma (MM)
Indication DetailsTreat MUC1-positive tumors; Treat multiple myeloma (MM)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today